Online citations, reference lists, and bibliographies.
← Back to Search

The Physiological Rationale For Oral Insulin Administration.

E. Arbit
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Insulin remains the most effective and durable drug in the armamentarium for the treatment of advanced-stage diabetes. Nevertheless, clinical studies have shown that even on insulin treatment, a significant percentage of patients fail to attain lasting glycemic control. Well-recognized reasons for this failure include issues related to patients' noncompliance with an injectable drug and the late stage at which insulin is prescribed, but less explicit reasons related to the nonphysiological way insulin is currently administered are equally important. Parenteral insulin targets peripheral tissue rather than the liver with pharmacokinetics that do not replicate the normal dynamics of endogenous insulin release. Oral insulin is one of several alternative methods of insulin administration that are in clinical stages of development. The oral route of insulin delivery takes advantage of the portal-hepatic route of absorption. A review of relevant physiology is herewith provided.
This paper references
10.1172/JCI114142
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.
L. Groop (1989)
10.2337/DIACARE.26.8.2231
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients.
M. Alvarsson (2003)
10.1016/S0950-351X(05)80207-1
Control of glycaemia.
J. Gerich (1993)
10.1007/BF00400282
Is muscle the major site of insulin resistance in Type 2 (non-insulin-dependent) diabetes mellitus?
J. Gerich (2004)
10.1210/JC.2002-021403
Advances in diagnosis and treatment of hyperinsulinism in infants and children.
C. Stanley (2002)
10.2337/diacare.3.1.9
Normalization of Plasma Insulin Profiles in Diabetic Subjects with Programmed Insulin Delivery
D. Schade (1980)
10.2337/DIACARE.22.3.403
Racial and ethnic differences in glycemic control of adults with type 2 diabetes.
M. Harris (1999)
10.1001/JAMA.1997.03550200039029
Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.
R. Hayward (1997)
10.2337/diacare.15.3.318
Pathogenesis of NIDDM: A Balanced Overview
R. DeFronzo (1992)
10.1016/0026-0495(80)90094-3
The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man.
E. Ferrannini (1980)
10.2337/DIABETES.51.2007.S109
Phasic insulin release and metabolic regulation in type 2 diabetes.
S. Del Prato (2002)
10.1097/00005792-199005000-00005
Remission in Non‐Insulin‐Dependent Diabetes Mellitus: Clinical Characteristics of Remission and Relapse in Black Patients
M. Banerji (1990)
10.1056/NEJM200105033441801
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
J. Tuomilehto (2001)
10.1001/JAMA.281.21.2005
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
R. Turner (1999)
10.1172/JCI7231
The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
C. Weyer (1999)
10.2337/diacare.20.9.1353
Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment
H. Ilkova (1997)
10.2337/DIACARE.24.6.983
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
P. Hollander (2001)
10.1007/s001250100580
The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus
R. Pratley (2001)
10.1172/JCI113339
Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
K. Polonsky (1988)
10.2337/diab.37.6.736
Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes
D. Bruce (1988)
10.1038/OBY.2002.21
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
N. Paquot (2002)
10.1517/14656566.1.7.1455
A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of Type 2 diabetes
R. Moses (2000)
10.1056/NEJM199904153401505
Clinical features of 52 neonates with hyperinsulinism.
P. de Lonlay-Debeney (1999)
Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients.
P. Oskarsson (2000)
10.2337/DIABETES.51.9.2796
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
T. Buchanan (2002)
10.1056/NEJMCP021106
Initial Management of Glycemia in Type 2 Diabetes Mellitus
D. Nathan (2002)
10.2337/diacare.26.6.1902
Hypoglycemia in diabetes.
P. Cryer (2003)
10.1042/CS0880427
Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type I diabetic patients on continuous ambulatory peritoneal dialysis treatment.
J. Lahtela (1995)
10.1016/0026-0495(88)90023-6
Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus.
P. Campbell (1988)
10.1016/J.ARCMED.2005.03.012
Insulin therapy: current alternatives.
F. Gómez-Pérez (2005)
10.1177/000992288802700508
Neonatal Diabetes Mellitus in First Cousins
P. M. Mathew (1988)
10.2337/DIABETES.48.5.1198
Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
A. Cherrington (1999)
10.2337/diacare.3.2.229
The Peritoneum — A Potential Insulin Delivery Route for a Mechanical Pancreas
D. Schade (1980)
10.2337/diacare.19.7.780
Decreased Severe Hypoglycemia Frequency During Intraperitoneal Insulin Infusion Using Programmable Implantame Pumps
N. Jeandidier (1996)
10.1007/s001250051286
Insulin analogues and their potential in the management of diabetes mellitus
G. Bolli (1999)
10.1177/089686089401400206
Insulin Therapy in Uremic Diabetic Patients on Continuous Ambulatory Peritoneal Diaysis; Comparison of Intraperitoneal and Subcutaneous Administration
L. Scarpioni (1994)
10.1172/JCI113489
Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load.
D. Kelley (1988)
10.2337/DIABETES.50.6.1449
Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance.
P. Båvenholm (2001)
10.2337/diacare.18.8.1113
Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial
C. Abraira (1995)
10.2337/DIABETES.51.2007.S103
Physiological consequences of phasic insulin release in the normal animal.
A. Cherrington (2002)
10.1089/DIA.2005.7.948
Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes.
Gustaf Jederström (2005)
Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study.
R. Selgas (1989)
10.1046/j.1464-5491.2001.00395.x
Near‐normoglycaemic remission in African‐Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function
S. McFarlane (2001)
10.1152/AJPENDO.1981.240.6.E630
Dose-response characteristics for effects of insulin on production and utilization of glucose in man.
R. Rizza (1981)
10.2337/DIABETES.50.2.322
Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations.
A. Grimberg (2001)
10.1056/NEJM199201023260104
Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.
A. Mitrakou (1992)
10.2337/DIABETES.48.1.99
Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.
D. Bruttomesso (1999)
10.1210/EDRV.22.5.0442
Recombinant DNA technology in the treatment of diabetes: insulin analogs.
Z. Vajó (2001)
10.2337/diacare.18.3.388
Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study
H. Hanaire-Broutin (1995)
10.1002/DMRR.207
Development of oral insulin: progress and current status.
J. Still (2002)
10.1016/S1521-690X(03)00036-8
Regulation of hepatic and peripheral glucose disposal.
M. Moore (2003)
10.1016/S0140-6736(94)91462-1
French multicentre experience of implantable insulin pumps
C. Broussolle (1994)
10.1152/AJPENDO.1989.257.2.E241
Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans.
L. Luzi (1989)
10.2337/diacare.16.1.21
Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial
R. Henry (1993)
10.1056/NEJMOA012512
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
W. Knowler (2002)
10.1074/JBC.273.50.33501
Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration.
I. Efanova (1998)



This paper is referenced by
10.4155/TDE.11.129
Intestinal receptor targeting for peptide delivery: an expert's personal perspective on reasons for failure and new opportunities.
G. Russell-Jones (2011)
LONG-AWAITED DREAM OF ORAL INSULIN: WHERE DID WE REACH?
M. Madhav (2011)
Oral insulin delivery using pH-responsive hydrogel and gold nanoparticle hybrid carrier
C. Leung (2010)
10.1201/B15465-25
Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine
B. Wilffert (2014)
10.1039/d0bm00577k
Cholesterol moieties as building blocks for assembling nanoparticles to achieve effective oral delivery of insulin.
Y. Ding (2020)
10.1002/14651858.CD012327.pub2
Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews.
R. Martis (2018)
Oral Delivery of Insulin : Novel Approaches Amani
M. Elsayed (2018)
10.1177/0885328206060436
Insulin Loaded Eudragit L100 Microspheres for Oral Delivery: Preliminary in vitro Studies
D. Jain (2006)
10.1016/j.ejpb.2009.06.004
Formulation and characterization of an oily-based system for oral delivery of insulin.
A. Elsayed (2009)
10.1111/j.1463-1326.2009.01153.x
Open‐label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects
R. Eldor (2010)
10.5772/52265
Oral Delivery of Insulin: Novel Approaches
Amani M. Elsayed (2012)
10.1016/J.EJPS.2006.04.014
Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles.
N. Peppas (2006)
10.1517/17425247.2015.1018175
Polymeric nanoparticle drug delivery technologies for oral delivery applications
Eric M. Pridgen (2015)
10.1016/j.addr.2011.10.006
Oral colon delivery of insulin with the aid of functional adjuvants.
A. Maroni (2012)
10.2147/IJN.S81715
pH-sensitive poly(lactide-co-glycolide) nanoparticle composite microcapsules for oral delivery of insulin
S. Sun (2015)
Glucose-responsive Implantable Polymeric Microdevices for “Smart” Insulin Therapy of Diabetes
M. Chu (2014)
10.1016/j.ijbiomac.2020.02.079
Biodistribution and pharmacokinetics of thiolated chitosan nanoparticles for oral delivery of insulin in vivo.
S. Sudhakar (2020)
10.1016/J.EJPS.2006.06.008
Insulin encapsulation in reinforced alginate microspheres prepared by internal gelation.
Catarina M. Silva (2006)
10.2217/nnm.11.124
Nanomedicine for diabetes treatment.
H. Sung (2011)
10.1016/j.ijpharm.2018.07.041
Recent advancements in oral administration of insulin‐loaded liposomal drug delivery systems for diabetes mellitus
Chun Y Wong (2018)
10.1248/bpb.b17-00951
Combination Strategy with Complexation Hydrogels and Cell-Penetrating Peptides for Oral Delivery of Insulin.
Yu Fukuoka (2018)
10.1016/j.clinthera.2012.11.004
Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
J. Li (2012)
10.15406/MOJBB.2017.03.00030
Mucoadhesive microspheres of chitosan and polyvinyl alcohol as a carrier for intranasal delivery of insulin: in vitro and in vivo studies
Samira Nasiri Zadeh (2017)
10.1177/193229680900300627
Hepatic-Directed Vesicle Insulin: A Review of Formulation Development and Preclinical Evaluation
W. Geho (2009)
10.1016/j.addr.2012.10.010
Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules.
M. Chen (2013)
10.3109/03639045.2013.841187
Lyophilized insulin nanoparticles prepared from quaternized N-aryl derivatives of chitosan as a new strategy for oral delivery of insulin: in vitro, ex vivo and in vivo characterizations
Reza Mahjub (2014)
10.1016/j.ejpb.2009.06.002
Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin.
Camile B. Woitiski (2009)
10.4172/2157-7439.S4-007
Oral nano-insulin therapy: current progress on nanoparticle-based devices for intestinal epithelium-targeted insulin delivery
A. Ahmad (2011)
10.3109/02652048.2011.576782
Poly(N-vinylcaprolactam-co-methacrylic acid) hydrogel microparticles for oral insulin delivery
R. C. Mundargi (2011)
10.1089/DIA.2005.7.948
Blood glucose-lowering activity of a hyaluronan-insulin complex after oral administration to rats with diabetes.
Gustaf Jederström (2005)
10.1080/02652040801903843
Improved bioavailability of orally delivered insulin using Eudragit-L30D coated PLGA microparticles
Pratap C. Naha (2008)
Personalized Diagnosis and Therapy
G€unter M€uller (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar